Diabetes, Lipids, and CV Risk
Purpose of Review Diabetes is often associated with diabetic dyslipidemia. Both hyperglycemia and disorders of lipid metabolism strongly contribute to development of atherosclerosis, the crucial factor of cardiovascular disease. The aim of the manuscript is to summarize possible treatment to reduce...
Saved in:
| Published in | Current atherosclerosis reports Vol. 23; no. 3; p. 8 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | English |
| Published |
New York
Springer US
01.03.2021
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1523-3804 1534-6242 1534-6242 |
| DOI | 10.1007/s11883-021-00905-8 |
Cover
| Abstract | Purpose of Review
Diabetes is often associated with diabetic dyslipidemia. Both hyperglycemia and disorders of lipid metabolism strongly contribute to development of atherosclerosis, the crucial factor of cardiovascular disease. The aim of the manuscript is to summarize possible treatment to reduce cardiovascular risk.
Recent Findings
Maximal cardiovascular risk reduction is maintained by targeting more pathologic disturbances together. While antihypertensive treatment has not changed much recently, novel PCSK9 inhibitors have significantly improved management of dyslipidemia. Similarly, modern antihyperglycemic agents (SGLT2 inhibitors and GLP-1 receptor agonists) show both significant metabolic effects and cardiovascular benefits.
Summary
Diabetes treatment is no longer glucocentric. Apart from glucose management, there are effective pharmacologic tools for significant reduction of cardiovascular risk. |
|---|---|
| AbstractList | Purpose of Review
Diabetes is often associated with diabetic dyslipidemia. Both hyperglycemia and disorders of lipid metabolism strongly contribute to development of atherosclerosis, the crucial factor of cardiovascular disease. The aim of the manuscript is to summarize possible treatment to reduce cardiovascular risk.
Recent Findings
Maximal cardiovascular risk reduction is maintained by targeting more pathologic disturbances together. While antihypertensive treatment has not changed much recently, novel PCSK9 inhibitors have significantly improved management of dyslipidemia. Similarly, modern antihyperglycemic agents (SGLT2 inhibitors and GLP-1 receptor agonists) show both significant metabolic effects and cardiovascular benefits.
Summary
Diabetes treatment is no longer glucocentric. Apart from glucose management, there are effective pharmacologic tools for significant reduction of cardiovascular risk. Diabetes is often associated with diabetic dyslipidemia. Both hyperglycemia and disorders of lipid metabolism strongly contribute to development of atherosclerosis, the crucial factor of cardiovascular disease. The aim of the manuscript is to summarize possible treatment to reduce cardiovascular risk.PURPOSE OF REVIEWDiabetes is often associated with diabetic dyslipidemia. Both hyperglycemia and disorders of lipid metabolism strongly contribute to development of atherosclerosis, the crucial factor of cardiovascular disease. The aim of the manuscript is to summarize possible treatment to reduce cardiovascular risk.Maximal cardiovascular risk reduction is maintained by targeting more pathologic disturbances together. While antihypertensive treatment has not changed much recently, novel PCSK9 inhibitors have significantly improved management of dyslipidemia. Similarly, modern antihyperglycemic agents (SGLT2 inhibitors and GLP-1 receptor agonists) show both significant metabolic effects and cardiovascular benefits. Diabetes treatment is no longer glucocentric. Apart from glucose management, there are effective pharmacologic tools for significant reduction of cardiovascular risk.RECENT FINDINGSMaximal cardiovascular risk reduction is maintained by targeting more pathologic disturbances together. While antihypertensive treatment has not changed much recently, novel PCSK9 inhibitors have significantly improved management of dyslipidemia. Similarly, modern antihyperglycemic agents (SGLT2 inhibitors and GLP-1 receptor agonists) show both significant metabolic effects and cardiovascular benefits. Diabetes treatment is no longer glucocentric. Apart from glucose management, there are effective pharmacologic tools for significant reduction of cardiovascular risk. Diabetes is often associated with diabetic dyslipidemia. Both hyperglycemia and disorders of lipid metabolism strongly contribute to development of atherosclerosis, the crucial factor of cardiovascular disease. The aim of the manuscript is to summarize possible treatment to reduce cardiovascular risk. Maximal cardiovascular risk reduction is maintained by targeting more pathologic disturbances together. While antihypertensive treatment has not changed much recently, novel PCSK9 inhibitors have significantly improved management of dyslipidemia. Similarly, modern antihyperglycemic agents (SGLT2 inhibitors and GLP-1 receptor agonists) show both significant metabolic effects and cardiovascular benefits. Diabetes treatment is no longer glucocentric. Apart from glucose management, there are effective pharmacologic tools for significant reduction of cardiovascular risk. |
| ArticleNumber | 8 |
| Author | Škrha, Jan |
| Author_xml | – sequence: 1 givenname: Jan orcidid: 0000-0001-5388-8259 surname: Škrha fullname: Škrha, Jan email: jan.skrha2@LF1.cuni.cz organization: 3rd Department of Internal Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33464402$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kMtKAzEUQINU7EN_QFC6dGH05tUkS6lPKAiibkMmSSV1OlOTmYV_79RpNy5c3bs458I9YzSo6iogdErgigDI60yIUgwDJRhAg8DqAI2IYBzPKKeD7U4ZZgr4EI1zXgFQUDNyhIaM8RnnQEfo7DbaIjQhX04XcRN9N23lp_P36UvMn8focGnLHE52c4Le7u9e54948fzwNL9ZYMe4bHAB0hVce1tIoUB6TqgsFGeMWBF8INZZBdYL5mzhwWtL2RKYAO24FMQJNkEX_d1Nqr_akBuzjtmFsrRVqNtsKJcamBZaduj5Dm2LdfBmk-Lapm-zf6kDVA-4VOecwtK42Ngm1lWTbCwNAbOtZ_p6pqtnfusZ1an0j7q__q_Eeil3cPURklnVbaq6XP9ZP35Hfe4 |
| CitedBy_id | crossref_primary_10_1515_med_2024_1095 crossref_primary_10_1016_j_cca_2023_117444 crossref_primary_10_1016_j_jlr_2021_100164 crossref_primary_10_1136_bmjopen_2024_087954 crossref_primary_10_2147_DMSO_S449562 crossref_primary_10_1038_s41598_025_93908_3 crossref_primary_10_1186_s12889_024_19414_9 crossref_primary_10_1021_acs_jafc_1c06437 crossref_primary_10_3389_fnut_2024_1458536 crossref_primary_10_3389_fpubh_2024_1443104 crossref_primary_10_3389_fpubh_2024_1435004 |
| Cites_doi | 10.1097/hco.0000000000000762 10.1371/journal.pone.0090201 10.1056/NEJMoa1812389 10.1161/circulationaha.116.022194 10.1056/NEJMoa1107579 10.1056/NEJMoa1607141 10.1111/j.1463-1326.2006.00620.x 10.2337/dci19-0036 10.1001/jama.2011.1914 10.3390/nu11020298 10.1016/j.molmed.2020.03.011 10.1097/med.0000000000000551 10.1016/s0735-1097(01)01555-8 10.1161/circulationaha.118.038868 10.1093/eurheartj/ehz486 10.1016/S0140-6736(05)67528-9 10.1093/eurheartj/eht149 10.1056/NEJMoa1506930 10.1001/jama.2014.18574 10.1016/j.atherosclerosis.2012.01.019 10.1056/NEJMc1712572 10.1007/s00109-009-0439-2 10.1097/MOL.0000000000000474 10.4093/dmj.2015.39.5.353 10.1016/S2213-8587(20)30130-3 10.1056/NEJMoa0806470 10.1016/j.vph.2012.05.005 10.1186/s12872-020-01567-1 10.1007/s00125-015-3525-8 10.3390/jcm9040912 10.1016/S0140-6736(08)60104-X 10.1056/NEJMoa1801174 10.1007/s11886-020-01323-z 10.3390/ijms21051835 10.1016/s0140-6736(19)31149-3 10.1056/NEJMoa1410489 10.1056/NEJMoa1504720 10.1016/j.jcjd.2019.07.003 10.1016/s0140-6736(16)31357-5 10.1056/NEJMoa1615664 10.1056/NEJMoa1300955 10.1056/NEJMoa1603827 |
| ContentType | Journal Article |
| Copyright | The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature 2021 |
| Copyright_xml | – notice: The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature 2021 |
| DBID | AAYXX CITATION NPM 7X8 |
| DOI | 10.1007/s11883-021-00905-8 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1534-6242 |
| ExternalDocumentID | 33464402 10_1007_s11883_021_00905_8 |
| Genre | Journal Article Review |
| GroupedDBID | --- -5E -5G -BR -EM -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 1N0 203 29F 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2VQ 2~H 30V 4.4 406 408 40D 40E 53G 5GY 5VS 6J9 6NX 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABDZT ABECU ABFTV ABHQN ABIPD ABJNI ABJOX ABKCH ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTKH ABTMW ABWNU ABXPI ACAOD ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACREN ACSNA ACZOJ ADHHG ADHIR ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADYOE ADZKW AEBTG AEFQL AEGAL AEGNC AEGXH AEJHL AEJRE AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFLOW AFQWF AFWTZ AFYQB AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMTXH AMXSW AMYLF AMYQR AOCGG ARMRJ AXYYD B-. BA0 BDATZ BGNMA C1A CAG COF CS3 CSCUP CUW DDRTE DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMOBN ESBYG F5P FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 H13 HF~ HG6 HMJXF HRMNR HZ~ IJ- IKXTQ IMOTQ IWAJR IXC IXD IXE I~Z J-C JBSCW JZLTJ KOV LLZTM M4Y MA- N9A NB0 NPVJJ NQJWS NU0 O9- O9J P9S PF0 PT4 PT5 QOR QOS R89 R9I RNI ROL RPX RSV RZK S16 S1Z S27 S37 S3B SAP SDH SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 TSG TSK TSV TUC U2A U9L UG4 UOJIU UTJUX UZXMN VC2 VFIZW W48 WK8 YLTOR Z7U Z82 Z87 ZMTXR ZOVNA ~A9 AAPKM AAYXX ABBRH ABDBE ABFSG ACMFV ACSTC AEZWR AFDZB AFHIU AFOHR AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION NPM 7X8 ABRTQ |
| ID | FETCH-LOGICAL-c347t-b07cb49dab75807d4127b84331a5ede1aca80ad53cabd0d9a23f03509c4751c53 |
| IEDL.DBID | U2A |
| ISSN | 1523-3804 1534-6242 |
| IngestDate | Tue Aug 05 10:38:24 EDT 2025 Wed Feb 19 02:29:19 EST 2025 Tue Jul 01 04:14:29 EDT 2025 Thu Apr 24 22:52:55 EDT 2025 Fri Feb 21 02:49:07 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Prevention Diabetes Atherosclerosis Cardiovascular risk |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c347t-b07cb49dab75807d4127b84331a5ede1aca80ad53cabd0d9a23f03509c4751c53 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0001-5388-8259 |
| PMID | 33464402 |
| PQID | 2479039597 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2479039597 pubmed_primary_33464402 crossref_citationtrail_10_1007_s11883_021_00905_8 crossref_primary_10_1007_s11883_021_00905_8 springer_journals_10_1007_s11883_021_00905_8 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-03-01 |
| PublicationDateYYYYMMDD | 2021-03-01 |
| PublicationDate_xml | – month: 03 year: 2021 text: 2021-03-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | New York |
| PublicationPlace_xml | – name: New York – name: United States |
| PublicationTitle | Current atherosclerosis reports |
| PublicationTitleAbbrev | Curr Atheroscler Rep |
| PublicationTitleAlternate | Curr Atheroscler Rep |
| PublicationYear | 2021 |
| Publisher | Springer US |
| Publisher_xml | – name: Springer US |
| References | OsendeJIBadimonJJFusterVHersonPRabitoPVidhunRBlood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic controlJ Am Coll Cardiol2001385130713121:CAS:528:DC%2BD3MXovFKlsb4%3D10.1016/s0735-1097(01)01555-811691500 VergesBPathophysiology of diabetic dyslipidaemia: where are we?Diabetologia.20155858868991:CAS:528:DC%2BC2MXjvVCmu7k%3D10.1007/s00125-015-3525-8257256234392164 HsuHYLinCJLeeYSWuTHChienKLEfficacy of more intensive lipid-lowering therapy on cardiovascular diseases: a systematic review and meta-analysisBMC Cardiovasc Disord20202011210.1186/s12872-020-01567-1A meta-analysis of 103,864 patients in 18 trials comparing more intensive lipid-lowering and control groups. StahelPXiaoCLewisGFControl of intestinal lipoprotein secretion by dietary carbohydratesCurr Opin Lipidol201829124291:CAS:528:DC%2BC1cXit1ersQ%3D%3D10.1097/MOL.000000000000047429135691 InvestigatorsA-HBodenWEProbstfieldJLAndersonTChaitmanBRDesvignes-NickensPNiacin in patients with low HDL cholesterol levels receiving intensive statin therapyN Engl J Med201136524225522671:CAS:528:DC%2BC3MXhs1Ohu7jE10.1056/NEJMoa1107579 Group HTCLandrayMJHaynesRHopewellJCParishSAungTEffects of extended-release niacin with laropiprant in high-risk patientsN Engl J Med201437132032121:CAS:528:DC%2BC2cXhs1egsbvK10.1056/NEJMoa1300955 Patti AM, Rizvi AA, Giglio RV, Stoian AP, Ligi D, Mannello F. Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes. Journal of Clinical Medicine. 2020;9(4). https://doi.org/10.3390/jcm9040912. CerielloAThe emerging challenge in diabetes: the "metabolic memory"Vasc Pharmacol2012575–61331381:CAS:528:DC%2BC38XnslOjurk%3D10.1016/j.vph.2012.05.005 CollinsRReithCEmbersonJArmitageJBaigentCBlackwellLInterpretation of the evidence for the efficacy and safety of statin therapyLancet.201638810059253225611:CAS:528:DC%2BC28XhsV2gsr3E10.1016/s0140-6736(16)31357-527616593 DormandyJACharbonnelBEcklandDJErdmannEMassi-BenedettiMMoulesIKSecondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events): a randomised controlled trialLancet.20053669493127912891:CAS:528:DC%2BD2MXhtVOlu7fO10.1016/S0140-6736(05)67528-916214598 Cholesterol Treatment TrialistsCKearneyPMBlackwellLCollinsRKeechASimesJEfficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysisLancet.200837196071171251:CAS:528:DC%2BD1cXlt1Wquw%3D%3D10.1016/S0140-6736(08)60104-X WangCCLHessCNHiattWRGoldfineABClinical update: cardiovascular disease in diabetes mellitus atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerationsCirculation.2016133242459250210.1161/circulationaha.116.022194 KernanWNViscoliCMFurieKLYoungLHInzucchiSEGormanMPioglitazone after ischemic stroke or transient ischemic attackN Engl J Med201637414132113311:CAS:528:DC%2BC28XhtFGqsbbI10.1056/NEJMoa1506930268864184887756 ParhoferKGInteraction between glucose and lipid metabolism: more than diabetic dyslipidemiaDiabetes Metab J201539535336210.4093/dmj.2015.39.5.353265664924641964 Galmes S, Cifre M, Palou A, Oliver P, Serra F. A Genetic Score of Predisposition to Low-Grade Inflammation Associated with Obesity May Contribute to Discern Population at Risk for Metabolic Syndrome. Nutrients. 2019;11(2). https://doi.org/10.3390/nu11020298. Langlois MR, Sniderman AD. Non-HDL Cholesterol or apoB: Which to Prefer as a Target for the Prevention of Atherosclerotic Cardiovascular Disease? Current Cardiology Reports. 2020;22(8). https://doi.org/10.1007/s11886-020-01323-z. HolmanRRPaulSKBethelMAMatthewsDRNeilHA10-year follow-up of intensive glucose control in type 2 diabetesN Engl J Med200835915157715891:CAS:528:DC%2BD1cXht1Wgt7nK10.1056/NEJMoa080647018784090 GaedePHJepsenPVLarsenJNJensenGVParvingHHPedersenOBThe Steno-2 study. Intensive multifactorial intervention reduces the occurrence of cardiovascular disease in patients with type 2 diabetesUgeskr Laeger2003165262658266112886549 SjostromLPeltonenMJacobsonPSjostromCDKarasonKWedelHBariatric surgery and long-term cardiovascular eventsJAMA.20123071566510.1001/jama.2011.191422215166 HuangCLWuIHWuYWHwangJJWangSSChenWJAssociation of lower extremity arterial calcification with amputation and mortality in patients with symptomatic peripheral artery diseasePLoS One201492e902011:CAS:528:DC%2BC2cXhsVGqsbfJ10.1371/journal.pone.0090201245872793936008 CannonCPBlazingMAGiuglianoRPMcCaggAWhiteJATherouxPEzetimibe added to statin therapy after acute coronary syndromesN Engl J Med201537225238723971:CAS:528:DC%2BC2MXhtFyrtbbF10.1056/NEJMoa141048926039521 LazarteJHegeleRADyslipidemia Management in Adults with DiabetesCan J Diabetes2020441536010.1016/j.jcjd.2019.07.00331521544 ZinmanBWannerCLachinJMFitchettDBluhmkiEHantelSEmpagliflozin, cardiovascular outcomes, and mortality in type 2 diabetesN Engl J Med201537322211721281:CAS:528:DC%2BC28XntVSkurs%3D10.1056/NEJMoa1504720 EmdinCARahimiKNealBCallenderTPerkovicVPatelABlood pressure lowering in type 2 diabetes: a systematic review and meta-analysisJAMA.201531366036151:CAS:528:DC%2BC2MXjtVChsbo%3D10.1001/jama.2014.1857425668264 Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V, Orekhov AN. The Diabetes Mellitus-Atherosclerosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation. Int J Mol Sci. 2020;21(5). https://doi.org/10.3390/ijms21051835. YanSFRamasamyRSchmidtAMReceptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory responseJ Mol Med20098732352471:CAS:528:DC%2BD1MXitVOrtLo%3D10.1007/s00109-009-0439-219189073 SabatineMSGiuglianoRPKeechACHonarpourNWiviottSDMurphySAEvolocumab and clinical outcomes in patients with cardiovascular diseaseN Engl J Med201737618171317221:CAS:528:DC%2BC2sXhtlOns7nM10.1056/NEJMoa161566428304224 GoldbergRBStoneNJGrundySMThe 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA* guidelines on the Management of Blood Cholesterol in diabetesDiab Care20204381673167810.2337/dci19-0036Clinical practice guidelines recommendations on management of LDL cholesterol in people with diabetes. GersteinHCColhounHMDagenaisGRDiazRLakshmananMPaisPDulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialLancet.2019394101931211301:CAS:528:DC%2BC1MXhtFGjtb%2FN10.1016/s0140-6736(19)31149-331189511 PatelKVVaduganathanMTargeting multiple domains of residual cardiovascular disease risk in patients with diabetesCurr Opin Cardiol202035551752310.1097/hco.000000000000076232649348 ZelnikerTAWiviottSDRazIImKGoodrichELFurtadoRHMComparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Systematic Review and Meta-Analysis of Cardiovascular Outcomes TrialsCirculation201913917202220311:CAS:528:DC%2BC1MXnslOhu70%3D10.1161/circulationaha.118.03886830786725Systematic review and meta-analysis of cardiovascular outcomes trials with modern antihyperglycemic agents. PaneniFBeckmanJACreagerMACosentinoFDiabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part IEur Heart J20133431243624431:CAS:528:DC%2BC3sXht1yrs7%2FK10.1093/eurheartj/eht149236410073743069 Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019. https://doi.org/10.1093/eurheartj/ehz486. KohsakaSLamCSPKimDJCavenderMANorhammarAJorgensenMERisk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort studyLancet Diabetes & Endocrinology2020876066151:CAS:528:DC%2BB3cXht1SrsrfP10.1016/S2213-8587(20)30130-3 TellSNadeauKJEckelRHLipid management for cardiovascular risk reduction in type 1 diabetesCurrent Opinion in Endocrinology Diabetes and Obesity20202742072141:CAS:528:DC%2BB3cXhtlSktL%2FI10.1097/med.0000000000000551 IDF. IDF Diabetes Atlas. 9th Edition. 2019. MarsoSPBainSCConsoliAEliaschewitzFGJodarELeiterLASemaglutide and cardiovascular outcomes in patients with type 2 diabetesN Engl J Med201637519183418441:CAS:528:DC%2BC28XhvF2ksrfK10.1056/NEJMoa160714127633186 WangZJiangYLiuNRenLZhuYAnYAdvanced glycation end-product Nepsilon-carboxymethyl-lysine accelerates progression of atherosclerotic calcification in diabetesAtherosclerosis.201222123873961:CAS:528:DC%2BC38XhvVyjtrY%3D10.1016/j.atherosclerosis.2012.01.01922305260 ReuschJEDrazninBBAtherosclerosis in diabetes and insulin resistanceDiabetes Obes Metab2007944554631:CAS:528:DC%2BD2sXosF2ltr4%3D10.1111/j.1463-1326.2006.00620.x17587387 NealBPerkovicVMatthewsDRCanagliflozin and cardiovascular and renal events in type 2 diabetesN Engl J Med201737721209910.1056/NEJMc171257229166232 WiviottSDRazIBonacaMPMosenzonOKatoETCahnADapagliflozin and cardiovascular outcomes in type 2 diabetesNEJM.201938043473571:CAS:528:DC%2BC1MXit12rsLY%3D10.1056/NEJMoa181238930415602 MarsoSPDanielsGHBrown-FrandsenKKristensenPMannJFNauckMALiraglutide and cardiovascular outcomes in type 2 diabetesN Engl J Med201637543113221:CAS:528:DC%2BC28XhvF2ks77O10.1056/NEJMoa1603827272954274985288 SchwartzGGStegPGSzarekMBhattDLBittnerVADiazRAlirocumab and cardiovascular outcomes after acute coronary syndromeN Engl J Med201837922209721071:CAS:528:DC%2BC1cXisFSjs7vE10.1056/NEJMoa180117430403574 StitzielNOKanterJEBornfeldtKEEmerging targets for cardiovascular disease prevention in diabetesTrends Mol Med20202687447571:CAS:528:DC%2BB3cXnsleksr0%3D10.1016/j.molmed.2020.03.01132423639 B Zinman (905_CR32) 2015; 373 S Kohsaka (905_CR39) 2020; 8 CP Cannon (905_CR23) 2015; 372 JI Osende (905_CR11) 2001; 38 GG Schwartz (905_CR24) 2018; 379 Z Wang (905_CR6) 2012; 221 SF Yan (905_CR5) 2009; 87 JE Reusch (905_CR8) 2007; 9 NO Stitziel (905_CR44) 2020; 26 A Ceriello (905_CR13) 2012; 57 RR Holman (905_CR4) 2008; 359 B Verges (905_CR16) 2015; 58 R Collins (905_CR22) 2016; 388 SP Marso (905_CR36) 2016; 375 JA Dormandy (905_CR40) 2005; 366 RB Goldberg (905_CR26) 2020; 43 CCL Wang (905_CR2) 2016; 133 SD Wiviott (905_CR34) 2019; 380 F Paneni (905_CR3) 2013; 34 B Neal (905_CR33) 2017; 377 905_CR20 WN Kernan (905_CR9) 2016; 374 KG Parhofer (905_CR14) 2015; 39 MJ Landray (905_CR28) 2014; 371 TA Zelniker (905_CR38) 2019; 139 PH Gaede (905_CR17) 2003; 165 HY Hsu (905_CR19) 2020; 20 905_CR1 905_CR12 S Tell (905_CR15) 2020; 27 A-H Investigators (905_CR27) 2011; 365 P Stahel (905_CR30) 2018; 29 905_CR18 KV Patel (905_CR42) 2020; 35 905_CR10 C Cholesterol Treatment Trialists (905_CR21) 2008; 371 HC Gerstein (905_CR37) 2019; 394 CA Emdin (905_CR41) 2015; 313 CL Huang (905_CR7) 2014; 9 J Lazarte (905_CR29) 2020; 44 905_CR31 L Sjostrom (905_CR43) 2012; 307 MS Sabatine (905_CR25) 2017; 376 SP Marso (905_CR35) 2016; 375 |
| References_xml | – reference: PatelKVVaduganathanMTargeting multiple domains of residual cardiovascular disease risk in patients with diabetesCurr Opin Cardiol202035551752310.1097/hco.000000000000076232649348 – reference: WangZJiangYLiuNRenLZhuYAnYAdvanced glycation end-product Nepsilon-carboxymethyl-lysine accelerates progression of atherosclerotic calcification in diabetesAtherosclerosis.201222123873961:CAS:528:DC%2BC38XhvVyjtrY%3D10.1016/j.atherosclerosis.2012.01.01922305260 – reference: GaedePHJepsenPVLarsenJNJensenGVParvingHHPedersenOBThe Steno-2 study. Intensive multifactorial intervention reduces the occurrence of cardiovascular disease in patients with type 2 diabetesUgeskr Laeger2003165262658266112886549 – reference: ReuschJEDrazninBBAtherosclerosis in diabetes and insulin resistanceDiabetes Obes Metab2007944554631:CAS:528:DC%2BD2sXosF2ltr4%3D10.1111/j.1463-1326.2006.00620.x17587387 – reference: KernanWNViscoliCMFurieKLYoungLHInzucchiSEGormanMPioglitazone after ischemic stroke or transient ischemic attackN Engl J Med201637414132113311:CAS:528:DC%2BC28XhtFGqsbbI10.1056/NEJMoa1506930268864184887756 – reference: Cholesterol Treatment TrialistsCKearneyPMBlackwellLCollinsRKeechASimesJEfficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysisLancet.200837196071171251:CAS:528:DC%2BD1cXlt1Wquw%3D%3D10.1016/S0140-6736(08)60104-X – reference: CollinsRReithCEmbersonJArmitageJBaigentCBlackwellLInterpretation of the evidence for the efficacy and safety of statin therapyLancet.201638810059253225611:CAS:528:DC%2BC28XhsV2gsr3E10.1016/s0140-6736(16)31357-527616593 – reference: Patti AM, Rizvi AA, Giglio RV, Stoian AP, Ligi D, Mannello F. Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes. Journal of Clinical Medicine. 2020;9(4). https://doi.org/10.3390/jcm9040912. – reference: SabatineMSGiuglianoRPKeechACHonarpourNWiviottSDMurphySAEvolocumab and clinical outcomes in patients with cardiovascular diseaseN Engl J Med201737618171317221:CAS:528:DC%2BC2sXhtlOns7nM10.1056/NEJMoa161566428304224 – reference: StahelPXiaoCLewisGFControl of intestinal lipoprotein secretion by dietary carbohydratesCurr Opin Lipidol201829124291:CAS:528:DC%2BC1cXit1ersQ%3D%3D10.1097/MOL.000000000000047429135691 – reference: ZinmanBWannerCLachinJMFitchettDBluhmkiEHantelSEmpagliflozin, cardiovascular outcomes, and mortality in type 2 diabetesN Engl J Med201537322211721281:CAS:528:DC%2BC28XntVSkurs%3D10.1056/NEJMoa1504720 – reference: MarsoSPBainSCConsoliAEliaschewitzFGJodarELeiterLASemaglutide and cardiovascular outcomes in patients with type 2 diabetesN Engl J Med201637519183418441:CAS:528:DC%2BC28XhvF2ksrfK10.1056/NEJMoa160714127633186 – reference: WiviottSDRazIBonacaMPMosenzonOKatoETCahnADapagliflozin and cardiovascular outcomes in type 2 diabetesNEJM.201938043473571:CAS:528:DC%2BC1MXit12rsLY%3D10.1056/NEJMoa181238930415602 – reference: KohsakaSLamCSPKimDJCavenderMANorhammarAJorgensenMERisk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort studyLancet Diabetes & Endocrinology2020876066151:CAS:528:DC%2BB3cXht1SrsrfP10.1016/S2213-8587(20)30130-3 – reference: NealBPerkovicVMatthewsDRCanagliflozin and cardiovascular and renal events in type 2 diabetesN Engl J Med201737721209910.1056/NEJMc171257229166232 – reference: Langlois MR, Sniderman AD. Non-HDL Cholesterol or apoB: Which to Prefer as a Target for the Prevention of Atherosclerotic Cardiovascular Disease? Current Cardiology Reports. 2020;22(8). https://doi.org/10.1007/s11886-020-01323-z. – reference: YanSFRamasamyRSchmidtAMReceptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory responseJ Mol Med20098732352471:CAS:528:DC%2BD1MXitVOrtLo%3D10.1007/s00109-009-0439-219189073 – reference: EmdinCARahimiKNealBCallenderTPerkovicVPatelABlood pressure lowering in type 2 diabetes: a systematic review and meta-analysisJAMA.201531366036151:CAS:528:DC%2BC2MXjtVChsbo%3D10.1001/jama.2014.1857425668264 – reference: GoldbergRBStoneNJGrundySMThe 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA* guidelines on the Management of Blood Cholesterol in diabetesDiab Care20204381673167810.2337/dci19-0036Clinical practice guidelines recommendations on management of LDL cholesterol in people with diabetes. – reference: Group HTCLandrayMJHaynesRHopewellJCParishSAungTEffects of extended-release niacin with laropiprant in high-risk patientsN Engl J Med201437132032121:CAS:528:DC%2BC2cXhs1egsbvK10.1056/NEJMoa1300955 – reference: GersteinHCColhounHMDagenaisGRDiazRLakshmananMPaisPDulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialLancet.2019394101931211301:CAS:528:DC%2BC1MXhtFGjtb%2FN10.1016/s0140-6736(19)31149-331189511 – reference: HsuHYLinCJLeeYSWuTHChienKLEfficacy of more intensive lipid-lowering therapy on cardiovascular diseases: a systematic review and meta-analysisBMC Cardiovasc Disord20202011210.1186/s12872-020-01567-1A meta-analysis of 103,864 patients in 18 trials comparing more intensive lipid-lowering and control groups. – reference: Galmes S, Cifre M, Palou A, Oliver P, Serra F. A Genetic Score of Predisposition to Low-Grade Inflammation Associated with Obesity May Contribute to Discern Population at Risk for Metabolic Syndrome. Nutrients. 2019;11(2). https://doi.org/10.3390/nu11020298. – reference: ParhoferKGInteraction between glucose and lipid metabolism: more than diabetic dyslipidemiaDiabetes Metab J201539535336210.4093/dmj.2015.39.5.353265664924641964 – reference: CerielloAThe emerging challenge in diabetes: the "metabolic memory"Vasc Pharmacol2012575–61331381:CAS:528:DC%2BC38XnslOjurk%3D10.1016/j.vph.2012.05.005 – reference: CannonCPBlazingMAGiuglianoRPMcCaggAWhiteJATherouxPEzetimibe added to statin therapy after acute coronary syndromesN Engl J Med201537225238723971:CAS:528:DC%2BC2MXhtFyrtbbF10.1056/NEJMoa141048926039521 – reference: TellSNadeauKJEckelRHLipid management for cardiovascular risk reduction in type 1 diabetesCurrent Opinion in Endocrinology Diabetes and Obesity20202742072141:CAS:528:DC%2BB3cXhtlSktL%2FI10.1097/med.0000000000000551 – reference: Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019. https://doi.org/10.1093/eurheartj/ehz486. – reference: SchwartzGGStegPGSzarekMBhattDLBittnerVADiazRAlirocumab and cardiovascular outcomes after acute coronary syndromeN Engl J Med201837922209721071:CAS:528:DC%2BC1cXisFSjs7vE10.1056/NEJMoa180117430403574 – reference: ZelnikerTAWiviottSDRazIImKGoodrichELFurtadoRHMComparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Systematic Review and Meta-Analysis of Cardiovascular Outcomes TrialsCirculation201913917202220311:CAS:528:DC%2BC1MXnslOhu70%3D10.1161/circulationaha.118.03886830786725Systematic review and meta-analysis of cardiovascular outcomes trials with modern antihyperglycemic agents. – reference: InvestigatorsA-HBodenWEProbstfieldJLAndersonTChaitmanBRDesvignes-NickensPNiacin in patients with low HDL cholesterol levels receiving intensive statin therapyN Engl J Med201136524225522671:CAS:528:DC%2BC3MXhs1Ohu7jE10.1056/NEJMoa1107579 – reference: SjostromLPeltonenMJacobsonPSjostromCDKarasonKWedelHBariatric surgery and long-term cardiovascular eventsJAMA.20123071566510.1001/jama.2011.191422215166 – reference: LazarteJHegeleRADyslipidemia Management in Adults with DiabetesCan J Diabetes2020441536010.1016/j.jcjd.2019.07.00331521544 – reference: OsendeJIBadimonJJFusterVHersonPRabitoPVidhunRBlood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic controlJ Am Coll Cardiol2001385130713121:CAS:528:DC%2BD3MXovFKlsb4%3D10.1016/s0735-1097(01)01555-811691500 – reference: DormandyJACharbonnelBEcklandDJErdmannEMassi-BenedettiMMoulesIKSecondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events): a randomised controlled trialLancet.20053669493127912891:CAS:528:DC%2BD2MXhtVOlu7fO10.1016/S0140-6736(05)67528-916214598 – reference: StitzielNOKanterJEBornfeldtKEEmerging targets for cardiovascular disease prevention in diabetesTrends Mol Med20202687447571:CAS:528:DC%2BB3cXnsleksr0%3D10.1016/j.molmed.2020.03.01132423639 – reference: MarsoSPDanielsGHBrown-FrandsenKKristensenPMannJFNauckMALiraglutide and cardiovascular outcomes in type 2 diabetesN Engl J Med201637543113221:CAS:528:DC%2BC28XhvF2ks77O10.1056/NEJMoa1603827272954274985288 – reference: HolmanRRPaulSKBethelMAMatthewsDRNeilHA10-year follow-up of intensive glucose control in type 2 diabetesN Engl J Med200835915157715891:CAS:528:DC%2BD1cXht1Wgt7nK10.1056/NEJMoa080647018784090 – reference: VergesBPathophysiology of diabetic dyslipidaemia: where are we?Diabetologia.20155858868991:CAS:528:DC%2BC2MXjvVCmu7k%3D10.1007/s00125-015-3525-8257256234392164 – reference: IDF. IDF Diabetes Atlas. 9th Edition. 2019. – reference: Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V, Orekhov AN. The Diabetes Mellitus-Atherosclerosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation. Int J Mol Sci. 2020;21(5). https://doi.org/10.3390/ijms21051835. – reference: HuangCLWuIHWuYWHwangJJWangSSChenWJAssociation of lower extremity arterial calcification with amputation and mortality in patients with symptomatic peripheral artery diseasePLoS One201492e902011:CAS:528:DC%2BC2cXhsVGqsbfJ10.1371/journal.pone.0090201245872793936008 – reference: WangCCLHessCNHiattWRGoldfineABClinical update: cardiovascular disease in diabetes mellitus atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerationsCirculation.2016133242459250210.1161/circulationaha.116.022194 – reference: PaneniFBeckmanJACreagerMACosentinoFDiabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part IEur Heart J20133431243624431:CAS:528:DC%2BC3sXht1yrs7%2FK10.1093/eurheartj/eht149236410073743069 – volume: 35 start-page: 517 issue: 5 year: 2020 ident: 905_CR42 publication-title: Curr Opin Cardiol doi: 10.1097/hco.0000000000000762 – volume: 9 start-page: e90201 issue: 2 year: 2014 ident: 905_CR7 publication-title: PLoS One doi: 10.1371/journal.pone.0090201 – volume: 380 start-page: 347 issue: 4 year: 2019 ident: 905_CR34 publication-title: NEJM. doi: 10.1056/NEJMoa1812389 – volume: 133 start-page: 2459 issue: 24 year: 2016 ident: 905_CR2 publication-title: Circulation. doi: 10.1161/circulationaha.116.022194 – volume: 365 start-page: 2255 issue: 24 year: 2011 ident: 905_CR27 publication-title: N Engl J Med doi: 10.1056/NEJMoa1107579 – volume: 375 start-page: 1834 issue: 19 year: 2016 ident: 905_CR36 publication-title: N Engl J Med doi: 10.1056/NEJMoa1607141 – volume: 9 start-page: 455 issue: 4 year: 2007 ident: 905_CR8 publication-title: Diabetes Obes Metab doi: 10.1111/j.1463-1326.2006.00620.x – volume: 43 start-page: 1673 issue: 8 year: 2020 ident: 905_CR26 publication-title: Diab Care doi: 10.2337/dci19-0036 – volume: 307 start-page: 56 issue: 1 year: 2012 ident: 905_CR43 publication-title: JAMA. doi: 10.1001/jama.2011.1914 – ident: 905_CR10 doi: 10.3390/nu11020298 – volume: 26 start-page: 744 issue: 8 year: 2020 ident: 905_CR44 publication-title: Trends Mol Med doi: 10.1016/j.molmed.2020.03.011 – volume: 27 start-page: 207 issue: 4 year: 2020 ident: 905_CR15 publication-title: Current Opinion in Endocrinology Diabetes and Obesity doi: 10.1097/med.0000000000000551 – volume: 38 start-page: 1307 issue: 5 year: 2001 ident: 905_CR11 publication-title: J Am Coll Cardiol doi: 10.1016/s0735-1097(01)01555-8 – volume: 139 start-page: 2022 issue: 17 year: 2019 ident: 905_CR38 publication-title: Circulation doi: 10.1161/circulationaha.118.038868 – ident: 905_CR18 doi: 10.1093/eurheartj/ehz486 – volume: 165 start-page: 2658 issue: 26 year: 2003 ident: 905_CR17 publication-title: Ugeskr Laeger – volume: 366 start-page: 1279 issue: 9493 year: 2005 ident: 905_CR40 publication-title: Lancet. doi: 10.1016/S0140-6736(05)67528-9 – volume: 34 start-page: 2436 issue: 31 year: 2013 ident: 905_CR3 publication-title: Eur Heart J doi: 10.1093/eurheartj/eht149 – volume: 374 start-page: 1321 issue: 14 year: 2016 ident: 905_CR9 publication-title: N Engl J Med doi: 10.1056/NEJMoa1506930 – volume: 313 start-page: 603 issue: 6 year: 2015 ident: 905_CR41 publication-title: JAMA. doi: 10.1001/jama.2014.18574 – volume: 221 start-page: 387 issue: 2 year: 2012 ident: 905_CR6 publication-title: Atherosclerosis. doi: 10.1016/j.atherosclerosis.2012.01.019 – volume: 377 start-page: 2099 issue: 21 year: 2017 ident: 905_CR33 publication-title: N Engl J Med doi: 10.1056/NEJMc1712572 – ident: 905_CR1 – volume: 87 start-page: 235 issue: 3 year: 2009 ident: 905_CR5 publication-title: J Mol Med doi: 10.1007/s00109-009-0439-2 – volume: 29 start-page: 24 issue: 1 year: 2018 ident: 905_CR30 publication-title: Curr Opin Lipidol doi: 10.1097/MOL.0000000000000474 – volume: 39 start-page: 353 issue: 5 year: 2015 ident: 905_CR14 publication-title: Diabetes Metab J doi: 10.4093/dmj.2015.39.5.353 – volume: 8 start-page: 606 issue: 7 year: 2020 ident: 905_CR39 publication-title: Lancet Diabetes & Endocrinology doi: 10.1016/S2213-8587(20)30130-3 – volume: 359 start-page: 1577 issue: 15 year: 2008 ident: 905_CR4 publication-title: N Engl J Med doi: 10.1056/NEJMoa0806470 – volume: 57 start-page: 133 issue: 5–6 year: 2012 ident: 905_CR13 publication-title: Vasc Pharmacol doi: 10.1016/j.vph.2012.05.005 – volume: 20 start-page: 12 issue: 1 year: 2020 ident: 905_CR19 publication-title: BMC Cardiovasc Disord doi: 10.1186/s12872-020-01567-1 – volume: 58 start-page: 886 issue: 5 year: 2015 ident: 905_CR16 publication-title: Diabetologia. doi: 10.1007/s00125-015-3525-8 – ident: 905_CR31 doi: 10.3390/jcm9040912 – volume: 371 start-page: 117 issue: 9607 year: 2008 ident: 905_CR21 publication-title: Lancet. doi: 10.1016/S0140-6736(08)60104-X – volume: 379 start-page: 2097 issue: 22 year: 2018 ident: 905_CR24 publication-title: N Engl J Med doi: 10.1056/NEJMoa1801174 – ident: 905_CR20 doi: 10.1007/s11886-020-01323-z – ident: 905_CR12 doi: 10.3390/ijms21051835 – volume: 394 start-page: 121 issue: 10193 year: 2019 ident: 905_CR37 publication-title: Lancet. doi: 10.1016/s0140-6736(19)31149-3 – volume: 372 start-page: 2387 issue: 25 year: 2015 ident: 905_CR23 publication-title: N Engl J Med doi: 10.1056/NEJMoa1410489 – volume: 373 start-page: 2117 issue: 22 year: 2015 ident: 905_CR32 publication-title: N Engl J Med doi: 10.1056/NEJMoa1504720 – volume: 44 start-page: 53 issue: 1 year: 2020 ident: 905_CR29 publication-title: Can J Diabetes doi: 10.1016/j.jcjd.2019.07.003 – volume: 388 start-page: 2532 issue: 10059 year: 2016 ident: 905_CR22 publication-title: Lancet. doi: 10.1016/s0140-6736(16)31357-5 – volume: 376 start-page: 1713 issue: 18 year: 2017 ident: 905_CR25 publication-title: N Engl J Med doi: 10.1056/NEJMoa1615664 – volume: 371 start-page: 203 issue: 3 year: 2014 ident: 905_CR28 publication-title: N Engl J Med doi: 10.1056/NEJMoa1300955 – volume: 375 start-page: 311 issue: 4 year: 2016 ident: 905_CR35 publication-title: N Engl J Med doi: 10.1056/NEJMoa1603827 |
| SSID | ssj0020861 |
| Score | 2.3457806 |
| SecondaryResourceType | review_article |
| Snippet | Purpose of Review
Diabetes is often associated with diabetic dyslipidemia. Both hyperglycemia and disorders of lipid metabolism strongly contribute to... Diabetes is often associated with diabetic dyslipidemia. Both hyperglycemia and disorders of lipid metabolism strongly contribute to development of... |
| SourceID | proquest pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 8 |
| SubjectTerms | Angiology Cardiology Medicine Medicine & Public Health Section Editor Statin Drugs (R. Ceska Topical Collection on Statin Drugs |
| Title | Diabetes, Lipids, and CV Risk |
| URI | https://link.springer.com/article/10.1007/s11883-021-00905-8 https://www.ncbi.nlm.nih.gov/pubmed/33464402 https://www.proquest.com/docview/2479039597 |
| Volume | 23 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1dS8MwFL3oBuKL-G3VjQq-uULaJGvyOMbmUOaDOJlPIV8FUTqx2_836doNmQx86kua0pPb5lzOPTcAtzZmVrv02OUmRkUkpSTilPOIWCS19c5G5A3O46fuaEIepnRamcKKutq9liTLP_Xa7BYz5jVHl_4ijmjEdqFJfT8pF8WTpLdKsxxJX3ZJTXCEGSKVVebvOX5vRxscc0MfLbed4SEcVHwx7C0X-Ah2bH4Me-NKET-BVlXSUnRCfwy1cVeZm7D_Gj6_Fx-nMBkOXvqjqDryINKYpPNIoVQrwo1Ujsej1JA4SRXzriZJrbGx1JIhaSjWUhlkuExw5rVBrh3Msab4DBr5LLcXEDKiJOaWE2y6xGaZVJxn1nCSUcWzLg0grt9c6KofuD-W4lOsOxl7tIRDS5RoCRbA3eqer2U3jK2jb2pAhQtar0TI3M4WhUhIyhF2QZEGcL5EejUfxsRxNJQE0KmhF9V3VWx52OX_hl_BflKGga8mu4bG_HthW45ezFUbmr37t8dBu4yqH3mHwk8 |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8QwEB50BfXi-7E-K3jTLmmTbJPjIq7rYz2IK3oKeRVEqWJ3L_56k2264gPBU6GkaSczaWb45psBOLQJs9qFxy42MSomGSUxp5zHxCKprWc2Ik9w7l-3ewNycU_vAymsrLPda0hy_Kf-JLsljHnM0YW_iCMas2mYIe4ebcBM5-zh8nQSaDk3vaqTmuIYM0QCWeb3Wb4eSD-8zB8I6fjg6S7CoP7kKt_kqTUaqpZ-_1bN8b8yLcFC8ESjTmU6yzBlixWY7QesfRV2Q7JMeRz5BtfGXWVhopO76OaxfFqDQff09qQXh2YKscYkG8YKZVoRbqRyEQLKDEnSTDHPl5LUGptILRmShmItlUGGyxTnHnXk2ikw0RSvQ6N4KewmRIwoibnlBJs2sXkuFee5NZzkVPG8TZuQ1CsqdKg07htePIvPGslebuHkFmO5BWvC0eSZ16rOxp-jD2pFCbcdPMYhC_syKkVKMo6wM7esCRuVBifzYUyc94fSJhzX2hBhx5Z_vGzrf8P3Ya53278SV-fXl9swn46V63PWdqAxfBvZXefEDNVesNkPNfHgnQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dS8MwED90wvBF_LbqtIJvWpY2yZo8DnXMryHixLeQr4Io3XDb_2_SdpsyGfjUlzQlv1y533H3uwM4tzGz2oXHLjYxKiIpJRGnnEfEIqmtVzYiL3B-7LW6fXL3Rt9-qPiLavdpSrLUNPguTfm4OTRZcy58ixnz-UcXCiOOaMRWYY04X-2LuvpJexZyOcJedkxNcIQZIpVs5u89frumBb65kCstXFBnEzYq7hi2y8veghWbb0P9scqO70CjKm8ZXYZ-JLVxT5mb8Oo1fH4ffexCv3PzctWNqvEHkcYkHUcKpVoRbqRynB6lxp0vVcwrnCS1xsZSS4akoVhLZZDhMsGZzxNy7SCPNcV7UMsHuT2AkBElMbecYNMiNsuk4jyzhpOMKp61aADx9ORCV73B_YiKTzHvauzREg4tUaAlWAAXs3eGZWeMpavPpoAKZ8A-KyFzO5iMREJSjrAzkDSA_RLp2X4YE8fXUBLA5RR6Uf1joyUfO_zf8lOoP113xMNt7_4I1pPCInyR2THUxl8T23CsY6xOCsP6Bn5Lx-M |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Diabetes%2C+Lipids%2C+and+CV+Risk&rft.jtitle=Current+atherosclerosis+reports&rft.au=%C5%A0krha%2C+Jan&rft.date=2021-03-01&rft.issn=1523-3804&rft.eissn=1534-6242&rft.volume=23&rft.issue=3&rft_id=info:doi/10.1007%2Fs11883-021-00905-8&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s11883_021_00905_8 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1523-3804&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1523-3804&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1523-3804&client=summon |